SCHEDULE 14A INFORMATION
Proxy Statement Pursuant To Section 14(a) Of
The Securities Exchange Act Of 1934
Filed by the Registrant [X]
Filed by a Party other than the Registrant [_]
Check the appropriate box:
[_] Preliminary Proxy Statement
[_] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY
RULE 14A-6(E)(2))
[_] Definitive Proxy Statement
[_] Definitive Additional Materials
[X] Soliciting Material Pursuant to Section 240.14a-12
ICN Pharmaceuticals, Inc.
--------------------------------------------------------
(Name of Registrant as Specified in its Charter)
N/A
--------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
-------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
-------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
-------------------------------------------------------------------
(5) Total fee paid:
-------------------------------------------------------------------
[_] Fee paid previously with preliminary materials.
[_] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
-------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
-------------------------------------------------------------------
(3) Filing Party:
-------------------------------------------------------------------
(4) Date Filed:
-------------------------------------------------------------------
The following is the text of advertisements prepared by ICN
Pharmaceuticals, Inc. and appearing in the Monday April 8, 2002 edition of
Barron's.
[Logo of ICN Pharmaceuticals]
ICN Pharmaceuticals, Inc.
ICN's Stock Outperforms Major Indexes:
(For the 12 month period ending 3/20/02)*
o Drug Industry by......................42%
o DJIA(R)by.............................30%
o S&P MidCap Pharm by...................28%
o S&P 500 by............................38%
o NASDAQ by.............................40%
o Russell 1000 by.......................37%
Delivering Shareholder Value
*Source: Bloomberg, March 20,2002
DJIA(R) Dow Jones Industrial Average is a trademark of Dow Jones L.P.
ICN stockholders are strongly advised to read the proxy statement relating
to ICN's 2002 annual meeting of stockholders when it becomes available, as
it will contain important information. Stockholders will be able to obtain
this proxy statement, any amendments to the proxy statement and other
documents filed by ICN with the Securities and Exchange Commission for free
at the Internet website maintained by the Securities and Exchange
Commission at www.sec.gov. In addition, ICN will mail the proxy statement
to each stockholder of record on the record date to be established for the
stockholders meeting. ICN will also make additional copies of the proxy
statement and any amendments to the proxy statement available for free to
ICN's stockholders. Please direct your request for the proxy statement to
Investor Relations, ICN Pharmaceuticals, Inc., 3300 Hyland Avenue, Costa
Mesa, California 92626, telephone (714) 545-0100, extension 3013.
ICN, its executive officers and directors may be deemed to be participants
in the solicitation of proxies for ICN's 2002 annual meeting of
stockholders. Information regarding these participants is contained in a
filing under Rule 14a-12 filed by ICN with the Securities and Exchange
Commission on April 4, 2002.
This contains forward-looking statements that involve risks and
uncertainties, including but not limited to, projections of future sales,
operating income, returns on invested assets, regulatory approval
processes, and other risks detailed from time to time in the Company's
Securities and Exchange Commission filings.
[Logo of ICN Pharmaceuticals]
ICN Pharmaceuticals, Inc.
Delivers Record 4th Quarter
and Full Year Results 2001
o Record 4Q Revenues..................$262 million
o Record 4Q Operating Income..........$ 78 million
o Record 4Q Royalties ................$ 54 million
o Record Full Year Revenues ..........$858 million
o Record Full Year Pre-Tax Income.....$144 million
Delivering Shareholder Value
ICN stockholders are strongly advised to read the proxy statement relating
to ICN's 2002 annual meeting of stockholders when it becomes available, as
it will contain important information. Stockholders will be able to obtain
this proxy statement, any amendments to the proxy statement and other
documents filed by ICN with the Securities and Exchange Commission for free
at the Internet website maintained by the Securities and Exchange
Commission at www.sec.gov. In addition, ICN will mail the proxy statement
to each stockholder of record on the record date to be established for the
stockholders meeting. ICN will also make additional copies of the proxy
statement and any amendments to the proxy statement available for free to
ICN's stockholders. Please direct your request for the proxy statement to
Investor Relations, ICN Pharmaceuticals, Inc., 3300 Hyland Avenue, Costa
Mesa, California 92626, telephone (714) 545-0100, extension 3013.
ICN, its executive officers and directors may be deemed to be participants
in the solicitation of proxies for ICN's 2002 annual meeting of
stockholders. Information regarding these participants is contained in a
filing under Rule 14a-12 filed by ICN with the Securities and Exchange
Commission on April 4, 2002.
This contains forward-looking statements that involve risks and
uncertainties, including but not limited to, projections of future sales,
operating income, returns on invested assets, regulatory approval
processes, and other risks detailed from time to time in the Company's
Securities and Exchange Commission filings.